Melane Sampson, Author at BioTuesdays

Developments

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) SVP of clinical pharmacology and analytics, Dr. Patrick Mayo, gave a virtual presentation entitled, “CRV431 – From Benchtop to Bedside Clinical Development” at the 4th Global NASH...

April 29, 2021

Markets

HCW starts Adicet Bio at buy; PT $27

H.C. Wainwright launched coverage of Adicet Bio (NASDAQ:ACET) with a “buy” rating and $27 price target. The stock closed at $13.11 on April 22. Adicet is focused on developing allogeneic gamma-delta T-cell therapies for...

April 23, 2021

Developments

Ripple Therapeutics treats first patient in DME, RVO Phase 2 trial

The first patient has been treated in Ripple Therapeutics’ RIPPLE-1 Phase 2 trial evaluating IBE-814 IVT, a proprietary intravitreal dexamethasone implant targeting inflammatory retinal diseases. RIPPLE-1 is a single...

April 20, 2021

Markets

Echelon starts Cognetivity Neurosciences at speculative buy; PT 85 cents (Canadian)

Echelon Capital Markets initiated coverage of Cognetivity Neurosciences (CSE:CGN; OTCQB:CGNSF)) with a “speculative buy” rating and price target of 85 cents (Canadian). The stock closed at 48.5 cents on April 16...

April 19, 2021

Markets

SVB Leerink starts Connect Biopharma at OP; PT $32

SVB Leerink launched coverage of Connect Biopharma Holdings (NASDAQ:CNTB) with an “outperform” rating and price target of $32. The stock closed at $17.05 on April 12. Connect is a clinical-stage biotech headquartered in...

April 13, 2021

Developments

TransMedics receives positive FDA advisory committee vote for OCS Heart System

The FDA’s Circulatory Systems Device Advisory Panel issued a favorable vote in support of approval of TransMedics Group’s (NASDAQ:TMDX) OCS Heart System to the FDA’s Office of Health Technology 2 (Cardiovascular...

April 7, 2021

Markets

Cantor starts Longboard Pharma at OW; PT $32

Cantor Fitzgerald launched coverage of Longboard Pharmaceuticals (NASDAQ:LBPH) with an “overweight” rating and $32 price target. The stock closed at $16.67 on April 5. Longboard was spun out of Arena Pharmaceuticals...

April 6, 2021

Markets

Raymond James ups Perimeter Medical Imaging PT to $6.50 (Canadian) from $3

Raymond James raised its price target for Perimeter Medical Imaging (TSXV:PINK) to $6.50 (Canadian) from $3, citing a deeper look at the artificial intelligence-enabled application of the company’s Optical...

April 5, 2021

Markets

Cantor starts Lineage Cell Therapeutics at OW; PT $6

Cantor Fitzgerald launched coverage of Lineage Cell Therapeutics (NYSE American: LCTX) with an “overweight” rating and 12-month price target of $6. The stock closed at $2.26 on March 30. Lineage is an allogeneic cell...

March 31, 2021

Markets

Cantor starts Aytu BioPharma at OW; PT $11

Cantor Fitzgerald launched coverage of Aytu BioPharma (NASDAQ:AYTU) with an “overweight” rating and $11 price target. The stock closed at $7.49 on March 29. “Through a strategy of in-licensing and acquisition-based...

March 29, 2021

Author - Melane Sampson

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

HCW starts Adicet Bio at buy; PT $27

Ripple Therapeutics treats first patient in DME, RVO Phase 2 trial

Echelon starts Cognetivity Neurosciences at speculative buy; PT 85 cents (Canadian)

SVB Leerink starts Connect Biopharma at OP; PT $32

TransMedics receives positive FDA advisory committee vote for OCS Heart System

Cantor starts Longboard Pharma at OW; PT $32

Raymond James ups Perimeter Medical Imaging PT to $6.50 (Canadian) from $3

Cantor starts Lineage Cell Therapeutics at OW; PT $6

Cantor starts Aytu BioPharma at OW; PT $11

Subscribe